EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Update on the Pathophysiology, Aetiology and Management of Central Sleep Apnoea

Sahan D Chandrasekara, Matthew T Naughton iD

Respirology · 2026

DOI: 10.1002/resp.70286 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Respirology, 2026. Verfasst von Sahan D Chandrasekara und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Alfred Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Sleep Apnea, Central. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Central sleep apnoea (CSA) of the periodic breathing type occurs during the transition between wakefulness and stage 1 and 2 non‐REM sleep. In adults at sea level, it occurs most commonly due to advanced heart failure (HF) or chronic opioid use and in ~5% of obstructive sleep apnoea patients initiating CPAP. The sudden development of CSA in a chronic CPAP user for obstructive sleep apnoea (OSA) may indicate the development of atrial fibrillation. Less commonly, idiopathic CSA occurs in which cardiac, neurological and endocrine causes should be excluded. Each cause of CSA has a characteristic appearance of apnoea, hyperpnoea and cycle length. Altitude induced CSA has recently been shown to reduce work of breathing whilst maintaining gas exchange, compared with regular breathing and thereby be considered adaptive rather than detrimental. The management of each type of CSA should be directed at the cause. Where there is residual CSA (e.g., post intensive treatment for HF), debate exists as to the next option. One argument is that CSA is adaptive (as seen with altitude) and therapeutic. An alternative argument is to treat the CSA directly with therapies such as respiratory stimulants (e.g., acetazolamide), positive airway pressure (e.g., adaptive servo‐ventilation (ASV)), supplemental oxygen or phrenic nerve pacing. These four latter treatments remain speculative without strong foundations for recommending especially ASV in HF with reduced ejection fraction where increased mortality has been observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Apnea, CentralHumansContinuous Positive Airway PressureHeart FailureAltitude

Stichwörter der Autor:innen

central sleep apnoeaheart failureperiodic breathing

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Alfred Hospital, Melbourne, Victoria, Australia.
  • School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.

ORCID-Profile: Matthew T Naughton

Zitieren

APA

Chandrasekara, S. D., & Naughton, M. T. (2026). Update on the Pathophysiology, Aetiology and Management of Central Sleep Apnoea. Respirology. https://doi.org/10.1002/resp.70286

Vancouver

Chandrasekara SD, Naughton MT. Update on the Pathophysiology, Aetiology and Management of Central Sleep Apnoea. Respirology. 2026. doi:10.1002/resp.70286

BibTeX
@article{Chandrasekara2026,
  author = {Chandrasekara, Sahan D and Naughton, Matthew T},
  title = {Update on the Pathophysiology, Aetiology and Management of Central Sleep Apnoea},
  journal = {Respirology},
  year = {2026},
  doi = {10.1002/resp.70286}
}
Kostenlos starten →